2016 Progress Report: Organotypic Liver Model for Predictive Human Toxicology and MetabolismEPA Grant Number: R835736C004
Subproject: this is subproject number 004 , established and managed by the Center Director under grant R835736
(EPA does not fund or establish subprojects; EPA awards and manages the overall grant for this center).
Center: Vanderbilt Pittsburgh Resource for Organotypic Models for Predictive Toxicology
Center Director: Hutson, Michael Shane
Title: Organotypic Liver Model for Predictive Human Toxicology and Metabolism
Investigators: Taylor, D. Lansing , Davidson, Jeffrey M. , Gough, Albert , Vernetti, Lawrence
Institution: University of Pittsburgh Main Campus , Vanderbilt University
EPA Project Officer: Klieforth, Barbara I
Project Period: December 1, 2014 through November 30, 2018 (Extended to November 30, 2019)
Project Period Covered by this Report: December 1, 2015 through November 30,2016
RFA: Organotypic Culture Models for Predictive Toxicology Center (2013) RFA Text | Recipients Lists
Research Category: Safer Chemicals , Health , Human Health
Our second year VPROMPT Center goals consisted of three milestones for the human liver organotypic culture model (OCM). One milestone was to demonstrate ion mobility mass spectroscopy (IM-MS/MS) application to secretome products from the liver OCM. The second milestone was to measure the toxicity responses of 15-20 ToxCast chemicals. The third milestone was to demonstrate liver OCM module compatibility on the Vanderbilt integrated platform.
The liver organotypic culture model (OCM) was developed and previously characterized in the Nortis commercial microfluidic device (Seattle, WA) at the Drug Discovery Institute laboratory of D. Lansing Taylor, University of Pittsburgh. The liver OCM consists of four human liver cell types (primary human hepatocytes, a Kupffer-like immune cell, stellate, and endothelial cells) that are constructed as a 3D, microfluidic tissue-like liver structure modeling the liver acinar organization. A subset of the human hepatocytes were transduced with a lentiviral construct to encode the hepatocyte genome with an expressible fluorescent cytochrome C protein in the mitochondria to monitor activation of apoptosis. Construction and use of the model and fluorescent protein transductions have been previously published (Vernetti, et al., 2015; Senutovitch, et al., 2015; Vernetti, et al., 2016).
In 2016, we used the liver OCM to compare the influx and efflux media for secretome substrates and metabolites of more than 1,600 compounds from biomolecules including but not limited to fatty acids; amino acids and dipeptides; carbohydrates; small organic acids; catecholamines; oils and lipids; pyrroles; and polyamines. MetaboAnalyst 3.0 analysis of the m/z and MS/MS fragmentation products obtained from IM-MS/MS secretome measurements found four unique pathways affected by tolcapone including histidine metabolism, propanoate metabolism, protein biosynthesis, and valine, leucine, and isoleucine degradation. The unique pathways affected by entacapone included aspartate metabolism, citric acid cycle, fructose and mannose degradation, galactose metabolism, mitochondrial electron transport chain, and phenylalanine and tyrosine metabolism. Additional analysis of results is planned to better understand the findings.
Seventeen compounds were tested at 1 or 2 concentrations for 18 days of treatment in the liver OCM. The cumulative incidents of adverse responses (an adverse response is defined as a 50% change from control for any of the following measurements: 18 LDH, 3 Albumin, 3 Urea, 2 Cytochrome C biosensor, and 1 each for Bile Efflux, TNF-α, and Testosterone clearance measurements) for the compounds shown in the figure. Out of a possible 29 toxicity measurements collected over the 18 day treatment period, the clinical hepatotoxins troglitazone, tolcapone, trovafloxacin, and nimesulide produced more adverse incidents than iDILI compounds such as valproic acid and warfarin or when compared to non-hepatotoxins caffeine or buspirone.
The third milestone, to incorporate the liver OCM into an integrated platform being developed at Vanderbilt University, will be completed in 2017.
In Year 3, we will complete the following milestones:
Milestone 11: Implement two new real-time, fluorescence-based biosensors of key physiological functions for liver and other organoids;
Milestone 12: Validate iPSC hepatocytes;
Milestone 13: Complete module compatibility on integrated platform;
Milestone 14: Test and optimize module for interaction with other tissue modules;
Milestone 15: Collaborate with other groups to incorporate mechanism-based fluorescent protein biosensors in other cells; and
Milestone 16: Validate all liver readouts on integrated platform.
Journal Articles on this Report : 3 Displayed | Download in RIS Format
|Other subproject views:||All 34 publications||10 publications in selected types||All 10 journal articles|
|Other center views:||All 149 publications||39 publications in selected types||All 39 journal articles|
||Senutovitch N, Vernetti L, Boltz R, DeBiasio R, Gough A, Taylor DL. Fluorescent protein biosensors applied to microphysiological systems. Experimental Biology and Medicine 2015;240(6):795-808.||
||Vernetti LA, Senutovitch N, Boltz R, DeBiasio R, Shun TY, Gough A, Taylor DL. A human liver microphysiology platform for investigating physiology, drug safety, and disease models. Experimental Biology and Medicine 2016;241(1):101-114.||
||Vernetti L, Gough A, Baetz N, Blutt S, Broughman JR, Brown JA, Foulke-Abel J, Hasan N, In J, Kelly E, Kovbasnjuk O, Repper J, Senutovitch N, Stabb J, Yeung C, Zachos NC, Donowitz M, Estes M, Himmelfarb J, Truskey G, Wikswo JP, Taylor DL. Functional coupling of human microphysiology systems: intestine, liver, kidney proximal tubule, blood-brain barrier and skeletal muscle. Scientific Reports 2017;7:42296 (15 pp.).||
Progress and Final Reports:Original Abstract
Main Center Abstract and Reports:R835736 Vanderbilt Pittsburgh Resource for Organotypic Models for Predictive Toxicology
Subprojects under this Center: (EPA does not fund or establish subprojects; EPA awards and manages the overall grant for this center).
R835736C001 Mammosphere Bioreactor For Life-Stage Specific Toxicology
R835736C002 Organotypic Culture Model to Analyze Developmental LimbMalformationsResulting from Toxicant/Teratogen Exposure
R835736C003 Validating a fetal membrane on a chip model for characterizing reproductive toxicant exposure risks
R835736C004 Organotypic Liver Model for Predictive Human Toxicology and Metabolism
R835736C005 Systems Engineering & Analysis for Organotypic Culture Models